Skip to content
DataLookout
Menu

VIRIDAENCT04515446

Quantification of Viral Load in the Upper Respiratory Tract in Patients Treated With Olsetamivir for Influenza

StatusTerminated
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial terminated Sponsor's reason: The study concerned Influenza. However, since it was launched at the time of COVID, influenza patients and studies were no more a priority. Therefore, inclusions were difficult. Show 5 more changesShow less
    • Eligibility criteria expanded, about 10 words
    • Study completion date changed from estimate of Mar 10, 2026 to Mar 10, 2023
    • Primary completion date: Mar 10, 2023 to Mar 9, 2023
    • Secondary endpoints: details revised at 2 of 3 entries
    • Publications: details revised at 3 of 3 entries
  2. Notable Primary completion date changed from estimate of Sep 1, 2021 to Mar 10, 2023v2 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 100 to confirmed 18
    • Study completion date: Oct 1, 2021 to Mar 10, 2026
    • Site details revised
  3. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed

Endpoints

Primary

The duration of influenza virus carriage in the upper airways in patients treated with olsetamivir will be observed
Timeframe: Within 8 days following patient's participation

Secondary (3)

Duration of influenza virus carriage in the upper airways among patients treated with olsetamivir according to the viral strand (A or B) will be mesured
Duration of influenza virus carriage in the upper airways among patients treated with olsetamivir according to their vaccination status and comorbidities will be mesured and compared
Difference in the number of days in isolation in patients hospitalized and treated with olsetamivir will be evaluated

Arms and interventions

TROD + PCR diagnosisOther

For each patient positive for flu with a rapid diagnostic test, sequential nasopharyngeal (NP) samples will be collected for quantitative PCR every day from D1 to D8 or until discharge (if before D8). Sequential quantitative PCR will quantify influenza virus load in the upper airways.

Diagnostic tests: Rapid test for diagnosis orientation, quantitative PCR

Sites

1 site in 1 country

  • Centre Hospitalier Princesse GraceMonaco, Municipality of Monaco, Monaco